

## **South Korea Anxiety Disorder and Depression Market Report and Forecast 2024-2032**

Market Report | 2024-08-08 | 160 pages | EMR Inc.

### **AVAILABLE LICENSES:**

- Single User License \$2999.00
- Five User License \$3999.00
- Corporate License \$4999.00

### **Report description:**

South Korea Anxiety Disorder and Depression Market Report and Forecast 2024-2032

The South Korea anxiety disorder and depression market was valued at USD 139.20 million in 2023. It is expected to grow at a CAGR of 3.8% between the forecast period of 2024 and 2032 and attain a market value of 181 million by 2032. UNICEF and BTS' collaboration for LOVE MYSELF CAMPAIGN, along with COVID-19 and lockdown significantly propel the growth of the industry in South Korea.

South Korea Anxiety Disorder and Depression Market Analysis

The anxiety disorder and depression market in South Korea has witnessed significant growth over the past decade. This growth is driven by increased awareness of mental health issues, advancements in medical technology, and the destigmatisation of mental health treatment. The market encompasses various segments, including pharmaceuticals, therapy services, and emerging digital mental health solutions.

Market Drivers

- ☐ **Rising Mental Health Awareness:** There has been a substantial increase in public awareness regarding mental health issues, leading to higher diagnosis rates and more people seeking treatment. Government campaigns and non-governmental organisations have played crucial roles in destigmatising mental health conditions.
- ☐ **Improved Healthcare Infrastructure:** South Korea boasts a robust healthcare system with easy access to mental health services. The government has been investing heavily in healthcare infrastructure, making mental health services more accessible to the general population.
- ☐ **Technological Advancements:** Innovations in pharmaceuticals and the rise of digital health solutions, such as mental health apps and telemedicine, have provided new avenues for treatment. These technologies offer convenience and have become increasingly popular, particularly among the younger population.
- ☐ **Government Initiatives and Policies:** The South Korean government has implemented several policies aimed at improving mental health care, including subsidising treatments and integrating mental health services into primary healthcare.

Market Challenges

- ☐ **Social Stigma:** Despite improvements, mental health stigma remains a significant barrier. Many individuals are still reluctant to seek help due to fear of social ostracisation and discrimination in the workplace or social circles.

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

- ☐ Limited Mental Health Professionals: There is a shortage of trained mental health professionals in South Korea. This limits the capacity to provide adequate care to the growing number of individuals seeking help.
- ☐ High Treatment Costs: While some treatments are subsidised, the cost of long-term therapy and medication can be prohibitive for many individuals, particularly those without comprehensive health insurance.
- ☐ Urban-Rural Disparities: Access to mental health services is often concentrated in urban areas, leaving rural populations underserved. This geographic disparity can lead to uneven treatment outcomes and increased mental health issues in less accessible regions.

#### Future Opportunities

- ☐ Expansion of Digital Health Solutions: The increasing penetration of smartphones and internet access provides a significant opportunity for the expansion of digital mental health solutions. These can offer scalable, cost-effective treatment options and support for individuals in both urban and rural areas.
- ☐ Public-Private Partnerships: Collaborations between the government and private sector can help bridge gaps in mental health services. These partnerships can drive innovations, improve service delivery, and increase funding for mental health initiatives.
- ☐ Workplace Mental Health Programmes: Implementing mental health programmes in workplaces can address stigma and promote early intervention. Employers can play a crucial role in supporting the mental well-being of their employees, leading to improved productivity and job satisfaction.
- ☐ Research and Development: Increased investment in research and development can lead to better understanding and treatment of anxiety and depression. This includes developing new medications with fewer side effects and more effective therapeutic approaches.
- ☐ Education and Training: Expanding education and training for mental health professionals is essential. By increasing the number of qualified professionals, South Korea can ensure that more people receive the care they need.

#### South Korea Anxiety Disorder and Depression Market Trends

The anxiety disorder and depression market in South Korea has witnessed significant growth over the past decade. This growth is driven by increased awareness of mental health issues, advancements in medical technology, and the destigmatisation of mental health treatment.

#### Market Trends

- ☐ Increase in Telehealth and Online Therapy: The adoption of telehealth and online therapy services has surged, especially post-pandemic. These services offer convenience and anonymity, making them attractive to individuals hesitant to seek face-to-face therapy.
- ☐ Growth in Prescription Medication: There has been a steady rise in the prescription of antidepressants and anxiolytics, supported by advancements in pharmaceutical research and an increasing number of individuals seeking medical treatment for mental health conditions.
- ☐ Rising Popularity of Mental Health Apps: Mental health apps providing services like meditation, cognitive behavioural therapy (CBT), and mood tracking are becoming increasingly popular. These apps cater to a tech-savvy population looking for accessible and affordable mental health support.
- ☐ Integration of Mental Health in Primary Care: There is a growing trend towards integrating mental health services into primary care settings. This approach aims to provide holistic care and early intervention, reducing the stigma associated with visiting specialised mental health facilities.
- ☐ Focus on Preventative Measures: Preventative mental health measures, including school-based mental health programmes and workplace wellness initiatives, are gaining traction. These programmes aim to identify and address mental health issues early, promoting long-term well-being.
- ☐ Increased Investment in Mental Health Research: Both government and private sectors are investing more in mental health research to develop innovative treatments and improve existing therapies. This trend is expected to drive future advancements in the market.
- ☐ Expansion of Support Groups and Community Services: There is a growing emphasis on community-based support groups and services, providing individuals with peer support and reducing feelings of isolation. These services play a crucial role in comprehensive mental health care.

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

## South Korea Anxiety Disorder and Depression Market Segmentation

### Market Breakup by Drug Type

- Antidepressant Drugs
  - o□ Selective Serotonin Reuptake Inhibitors (SSRIs)
  - o□ Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs)
  - o□ Tricyclic Antidepressants (TCAs)
  - o□ Monoamine Oxidase Inhibitors (MAOIs)
  - o□ Atypical Antipsychotics
  - o□ Benzodiazepines
  - o□ Anticonvulsants
  - o□ Beta-Blockers
  - o□ Others
- Therapy and Devices
  - o□ Fisher-Wallace Stimulator
  - o□ Transcranial Magnetic Stimulation (TMS)
  - o□ Deep Brain Stimulation (DBS)
  - o□ Vagus Nerve Stimulation (VNS)
  - o□ Electroconvulsive Therapy (ECT)
  - o□ Cognitive Behaviour Therapy (CBT)
  - o□ Others

The anxiety disorder and depression market in South Korea is segmented into drug types and therapy and devices. Key drug categories include Antidepressants such as SSRIs, SNRIs, TCAs, MAOIs, Atypical Antipsychotics, Benzodiazepines, Anticonvulsants, Beta-Blockers, and other medications. These drugs are pivotal market drivers due to rising mental health awareness and technological advancements in pharmaceuticals. The therapy and devices segment, including Fisher-Wallace Stimulator, Transcranial Magnetic Stimulation (TMS), Deep Brain Stimulation (DBS), Vagus Nerve Stimulation (VNS), Electroconvulsive Therapy (ECT), and Cognitive Behaviour Therapy (CBT), is expected to witness robust growth. Innovations in non-invasive treatments and increased adoption of digital therapy tools enhance accessibility and efficacy. These segments collectively drive market growth, offering comprehensive solutions for anxiety and depression. As awareness and acceptance of mental health treatments expand, these segments are poised to propel market growth significantly during the forecast period.

### Market Breakup by Indication

- Major Depressive Disorder (MDD)
- Obsessive-Compulsive Disorder (OCD)
- Phobia
- Others

The anxiety disorder and depression market in South Korea is segmented by indications, including Major Depressive Disorder (MDD), Obsessive-Compulsive Disorder (OCD), Phobia, and other related conditions. MDD remains a major market driver due to its high prevalence and the increasing demand for effective treatments. OCD and Phobia segments also contribute significantly, driven by heightened awareness and improved diagnostic practices. Additionally, the "Others" category, encompassing conditions like Generalised Anxiety Disorder (GAD) and Post-Traumatic Stress Disorder (PTSD), shows substantial growth potential. Future market expansion is anticipated as continued research, and development efforts yield new treatment options and therapeutic approaches. The increasing integration of digital health tools and personalised medicine is expected to enhance treatment outcomes, further propelling market growth. As mental health awareness and acceptance continue to rise, these segments are well-positioned to drive significant market growth during the forecast period.

### Market Breakup by Route of Administration

- Oral

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

-□□Topical

-□□Transdermal

The anxiety disorder and depression market in South Korea is segmented by the route of administration into Oral, Topical, and Transdermal categories. The Oral segment, comprising tablets and capsules, is the most prominent, driven by patient preference for convenience and ease of use. Topical administration, involving creams and gels, offers an alternative for those who may have difficulties with oral medications or require localised treatment. The Transdermal segment, which includes patches, is gaining traction due to its ability to provide steady medication release and improved patient compliance. Future market growth is anticipated as these routes of administration continue to evolve with advancements in drug delivery technologies. Enhanced bioavailability, reduced side effects, and personalised medication regimens are expected to further boost market expansion. As patient-centric approaches gain importance, these segments are poised to significantly drive market growth during the forecast period.

#### South Korea Anxiety Disorder and Depression Market Competitive Landscape

The competitive landscape of the anxiety disorder and depression market in South Korea is marked by prominent players such as Pfizer Inc. (Pfizer Korea Co., Ltd.), Eli Lilly and Company, H. Lundbeck A/S (Lundbeck Korea Co., Ltd.), Korea Otsuka Pharmaceutical Co., Ltd., Janssen Korea Co., Ltd. (Johnson & Johnson Services, Inc.), GSK plc., Allergan Korea Ltd (Abbvie), Mallinckrodt Inc., Jazz Pharmaceuticals, Inc., and Leading Pharma, LLC. These companies are actively engaged in market activities like mergers and acquisitions, research initiatives, product introductions, and strategic partnerships. Mergers and acquisitions are common, aiming to expand market reach and enhance product portfolios. Research initiatives focus on developing innovative therapies and improving existing treatments. Product introductions frequently bring new and improved medications to the market. Partnerships and collaborations are formed to leverage complementary strengths and enhance market presence. These activities collectively drive competitive dynamics and market growth.

#### Key Questions Answered in the Report

?□□What is the current and future performance of the South Korea anxiety disorder and depression market?

?□□What are the main challenges facing the South Korea anxiety disorder and depression market?

?□□What are the key drivers of the South Korea anxiety disorder and depression market?

?□□What emerging trends are shaping the future of the South Korea anxiety disorder and depression market?

?□□What challenges do high treatment costs and urban-rural disparities pose to mental health services?

?□□What factors are contributing to the steady rise in prescription medication for mental health conditions?

?□□How are rising mental health awareness and technological advancements driving growth in therapy and device segments?

?□□How is the transdermal segment contributing to market growth with steady medication release and patient compliance?

#### Key Benefits for Stakeholders

?□□The industry report offers a comprehensive quantitative analysis of various market segments, historical and current market trends, market forecasts, and dynamics of the South Korea anxiety disorder and depression market from 2017-2032.

?□□The research report provides the latest information on the market drivers, challenges, and opportunities in the South Korea anxiety disorder and depression market.

?□□The study maps the leading, as well as the fastest-growing, regional markets. It further enables stakeholders to identify the key country-level markets within each region.

?□□Porter's five forces analysis assists stakeholders in assessing the impact of new entrants, competitive rivalry, supplier power, buyer power, and the threat of substitution. It helps stakeholders to analyze the level of competition within the South Korea anxiety disorder and depression industry and its attractiveness.

?□□The competitive landscape allows stakeholders to understand their competitive environment and provides insight into the current positions of key players in the market.

#### Table of Contents:

1 Preface

2 Report Coverage - Key Segmentation and Scope

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 3 Report Description
  - 3.1 Market Definition and Outlook
  - 3.2 Properties and Applications
  - 3.3 Market Analysis
  - 3.4 Key Players
- 4 Key Assumptions
- 5 Executive Summary
  - 5.1 Overview
  - 5.2 Key Drivers
  - 5.3 Key Developments
  - 5.4 Competitive Structure
  - 5.5 Key Industrial Trends
- 6 Market Snapshot
- 7 Opportunities and Challenges in the Market
- 8 South Korea Anxiety Disorder and Depression Market Analysis
  - 8.1 Key Industry Highlights
  - 8.2 South Korea Anxiety Disorder and Depression Historical Market (2017-2023)
  - 8.3 South Korea Anxiety Disorder and Depression Market Forecast (2024-2032)
  - 8.4 South Korea Anxiety Disorder and Depression Market by Drug Class
    - 8.4.1 Antidepressant Drugs
      - 8.4.1.1 Market Share
      - 8.4.1.2 Historical Trend (2017-2023)
      - 8.4.1.3 Forecast Trend (2024-2032)
      - 8.4.1.4 Breakup by Type
        - 8.4.1.4.1 Selective Serotonin Reuptake Inhibitors (SSRIs)
        - 8.4.1.4.2 Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs)
        - 8.4.1.4.3 Tricyclic Antidepressants (TCAs)
        - 8.4.1.4.4 Monoamine Oxidase Inhibitors (MAOIs)
        - 8.4.1.4.5 Atypical Antipsychotics
        - 8.4.1.4.6 Benzodiazepines
        - 8.4.1.4.7 Anticonvulsants
        - 8.4.1.4.8 Beta-Blockers
        - 8.4.1.4.9 Others
    - 8.4.2 Therapy and Devices
      - 8.4.2.1 Market Share
      - 8.4.2.2 Historical Trend (2017-2023)
      - 8.4.2.3 Forecast Trend (2024-2032)
      - 8.4.2.4 Breakup by Type
        - 8.4.2.4.1 Fisher-Wallace Stimulator
        - 8.4.2.4.2 Transcranial Magnetic Stimulation (TMS)
        - 8.4.2.4.3 Deep Brain Stimulation (DBS)
        - 8.4.2.4.4 Vagus Nerve Stimulation (VNS)
        - 8.4.2.4.5 Electroconvulsive Therapy (ECT)
        - 8.4.2.4.6 Cognitive Behaviour Therapy (CBT)
        - 8.4.2.4.7 Others
  - 8.5 South Korea Anxiety Disorder and Depression Market by Indication
    - 8.5.1 Major Depressive Disorder (MDD)

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

- 8.5.1.1 Market Share
- 8.5.1.2 Historical Trend (2017-2023)
- 8.5.1.3 Forecast Trend (2024-2032)
- 8.5.2 Obsessive-Compulsive Disorder (OCD)
- 8.5.2.1 Market Share
- 8.5.2.2 Historical Trend (2017-2023)
- 8.5.2.3 Forecast Trend (2024-2032)
- 8.5.3 Phobia
- 8.5.3.1 Market Share
- 8.5.3.2 Historical Trend (2017-2023)
- 8.5.3.3 Forecast Trend (2024-2032)
- 9 Market Dynamics
- 9.1 SWOT Analysis
- 9.1.1 Strengths
- 9.1.2 Weaknesses
- 9.1.3 Opportunities
- 9.1.4 Threats
- 9.2 Porter's Five Forces Analysis
- 9.2.1 Supplier's Power
- 9.2.2 Buyer's Power
- 9.2.3 Threat of New Entrants
- 9.2.4 Degree of Rivalry
- 9.2.5 Threat of Substitutes
- 9.3 Key Indicators for Demand
- 9.4 Key Indicators for Price
- 10 Competitive Landscape
- 10.1 Market Structure
- 10.2 Company Profiles
- 10.2.1 Pfizer Inc. (Pfizer Korea Co., Ltd.)
- 10.2.1.1 Company Overview
- 10.2.1.2 Product Portfolio
- 10.2.1.3 Demographic Reach and Achievements
- 10.2.1.4 Certifications
- 10.2.2 Eli Lilly and Company
- 10.2.2.1 Company Overview
- 10.2.2.2 Product Portfolio
- 10.2.2.3 Demographic Reach and Achievements
- 10.2.2.4 Certifications
- 10.2.3 H. Lundbeck A/S (Lundbeck Korea Co., Ltd.)
- 10.2.3.1 Company Overview
- 10.2.3.2 Product Portfolio
- 10.2.3.3 Demographic Reach and Achievements
- 10.2.3.4 Certifications
- 10.2.4 Korea Otsuka Pharmaceutical Co., Ltd.
- 10.2.4.1 Company Overview
- 10.2.4.2 Product Portfolio
- 10.2.4.3 Demographic Reach and Achievements

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

10.2.4.4 Certifications

10.2.5 Janssen Korea Co., Ltd. (Johnson & Johnson Services, Inc.)

10.2.5.1 Company Overview

10.2.5.2 Product Portfolio

10.2.5.3 Demographic Reach and Achievements

10.2.5.4 Certifications

10.2.6 Others

11 Key Trends and Developments in the Market

List of Key Figures and Tables

1. South Korea Anxiety Disorder and Depression Market: Key Industry Highlights, 2017 and 2032
2. South Korea Anxiety Disorder and Depression Historical Market: Breakup by Drug Class (USD Million), 2017-2023
3. South Korea Anxiety Disorder and Depression Market Forecast: Breakup by Drug Class (USD Million), 2024-2032
4. South Korea Anxiety Disorder and Depression Historical Market: Breakup by Indication (USD Million), 2017-2023
5. South Korea Anxiety Disorder and Depression Market Forecast: Breakup by Indication (USD Million), 2024-2032
6. South Korea Anxiety Disorder and Depression Market Structure

## South Korea Anxiety Disorder and Depression Market Report and Forecast 2024-2032

Market Report | 2024-08-08 | 160 pages | EMR Inc.

To place an Order with Scotts International:

- ☐ - Print this form
- ☐ - Complete the relevant blank fields and sign
- ☐ - Send as a scanned email to support@scotts-international.com

### ORDER FORM:

Select license	License	Price
	Single User License	\$2999.00
	Five User License	\$3999.00
	Corporate License	\$4999.00
		VAT
		Total

\*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

☐ \*\* VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	<input type="text" value="2025-06-25"/>
		Signature	<input type="text"/>

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com